Myriad Genetics MYGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $200.4M-4.5% | $209.8M+2.0% | $205.7M-3.5% | $213.1M+8.8% | $195.9M-7.0% | ||
| $62.8M-0.3% | $63M+1.8% | $61.9M+1.0% | $61.3M-0.6% | $61.7M+3.4% | ||
| $137.6M-6.3% | $146.8M+2.1% | $143.8M-5.3% | $151.8M+13.1% | $134.2M-11.1% | ||
| 68.7%-1.3pp | 70%+0.1pp | 69.9%-1.3pp | 71.2%+2.7pp | 68.5%-3.1pp | ||
| $27.1M+6.3% | $25.5M-9.6% | $28.2M+10.2% | $25.6M-6.9% | $27.5M-14.6% | ||
| $73.6M+7.1% | $68.7M-3.2% | $71M-1.3% | $71.9M+3.9% | $69.2M-3.9% | ||
| $62.2M+11.9% | $55.6M-18.1% | $67.9M+1.6% | $66.8M+0.5% | $66.5M+3.9% | ||
| $168.3M+10.4% | $152.5M-8.7% | $167.1M-65.3% | $481M+195% | $163.2M-14.1% | ||
| $168.3M+10.4% | $152.5M-8.7% | $167.1M-65.3% | $481M+195% | $163.2M-14.1% | ||
| -$30.7M-439% | -$5.7M+75.5% | -$23.3M+92.9% | -$329.2M-1,035% | -$29M+25.6% | ||
| -15.3%-12.6pp | -2.7%+8.6pp | -11.3%+143pp | -154.5%-140pp | -14.8%+3.7pp | ||
| $4.1M-6.8% | $4.4M+15.8% | $3.8M+153% | $1.5M+87.5% | $800K+14.3% | ||
| $700K-12.5% | $800K+60.0% | $500K+150% | $200K-33.3% | $300K0.0% | ||
| -$3.4M-6.3% | -$3.2M-10.3% | -$2.9M-107% | -$1.4M-250% | -$400K-300% | ||
| -$34.1M-283% | -$8.9M+66.0% | -$26.2M+92.1% | -$330.6M-1,024% | -$29.4M+24.8% | ||
| $0+100% | -$1M-183% | $1.2M+1,300% | -$100K+99.7% | -$29.3M-962% | ||
| -$34.1M-332% | -$7.9M+71.2% | -$27.4M+91.7% | -$330.5M-330,400% | -$100K+99.8% | ||
| -17%-13.3pp | -3.8%+9.6pp | -13.3%+142pp | -155.1%-155pp | -0.1%+20.1pp | ||
| -$0.36-414% | -$0.07+75.9% | -$0.29+91.9% | -$3.57— | $0.00+100% | ||
| -$0.36-414% | -$0.07+75.9% | -$0.29+91.9% | -$3.57— | $0.00+100% | ||
| 93.7M+1.2% | 92.6M-0.5% | 93.1M+0.6% | 92.5M+1.2% | 91.4M+0.9% | ||
| 93.7M+1.2% | 92.6M-0.5% | 93.1M+0.6% | 92.5M+1.2% | 91.4M+0.9% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $0-100% | $400K0.0% | $400K+500% | -$100K-200% | $100K-66.7% | ||
| $200.4M-4.5% | $209.8M+2.0% | $205.7M-3.5% | $213.1M+8.8% | $195.9M-7.0% | ||
| $6.5M+132% | $2.8M-77.0% | $12.2M+14.0% | $10.7M+12.6% | $9.5M-12.8% | ||
| -$30.7M-439% | -$5.7M+75.5% | -$23.3M+92.9% | -$329.2M-1,035% | -$29M+25.6% | ||
| -$18.2M-364% | $6.9M+164% | -$10.7M+96.6% | -$315.1M-2,058% | -$14.6M+39.7% | ||
| -$18.2M-364% | $6.9M+164% | -$10.7M+96.6% | -$315.1M-2,058% | -$14.6M+39.7% | ||
| -9.1%-12.4pp | 3.3%+8.5pp | -5.2%+143pp | -147.9%-140pp | -7.5%+4.0pp | ||
| -$30.7M-439% | -$5.7M+75.5% | -$23.3M+92.9% | -$329.2M-1,035% | -$29M+25.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Myriad Genetics's revenue?
- Myriad Genetics (MYGN) generated $829.0M in revenue over the trailing twelve months, down 0.3% year over year.
- Is Myriad Genetics profitable?
- Myriad Genetics is not currently profitable: it reported a net loss of $399.9M over the trailing twelve months, a -48.2% net margin.
- What are Myriad Genetics's profit margins?
- Gross margin is 70.0% and operating margin is -46.9%, with a -48.2% net margin.
- What is Myriad Genetics's earnings per share?
- Myriad Genetics's diluted EPS over the trailing twelve months is $-4.29.
- Where does Myriad Genetics's income statement data come from?
- Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
